Editorial: Exploiting the Immune System to Treat Multiple Myeloma: From Transplantation to Novel Treatment Approaches

Niels W. C. J. van de Donk1, Efstathios Kastritis2 and Francesca Gay3*

1 Amsterdam UMC, Vrije Universiteit Amsterdam, Department of Hematology, Cancer Center Amsterdam, Amsterdam, Netherlands, 2 Plasma Cell Dyscrasia Unit, Department of Clinical Therapeutics, National and Kapodistrian University of Athens, Athens, Greece, 3 Division of Hematology, Citta della Salute e della Scienza, University of Torino, Torino, Italy

Keywords: myeloma, immunotherapy, immunoconjugate, CAR (chimeric antigen receptor) T cells, antibody

Editorial on the Research Topic

Exploiting the Immune System to Treat Multiple Myeloma: From Transplantation to Novel Treatment Approaches

During the last two decades, the survival of multiple myeloma (MM) patients has markedly improved due to the introduction of proteasome inhibitors (PIs; bortezomib, ixazomib, and carfilzomib) and immunomodulatory drugs (IMiDs; thalidomide, lenalidomide, and pomalidomide). In younger patients high-dose therapy and autologous stem cell transplantation have also contributed to prolonged disease control. More recently several new immunotherapeutic agents are transforming MM treatment. Naked monoclonal antibodies (defined as antibodies which have no drug or radionuclide attached to their Fc tail) were the first immunotherapeutic agents evaluated in MM, and several of these antibodies are now approved for the treatment of MM. First, the SLAMF7-targeting antibody, elotuzumab, can be effectively and safely combined with lenalidomide-dexamethasone (1) and pomalidomide-dexamethasone in relapsed/refractory MM (2). However, until now addition of elotuzumab to standards-of-care in newly diagnosed MM (NDMM) patients failed to improve response rate, progression-free survival (PFS) or overall survival (OS) (3, 4). In contrast, addition of the first-in-class CD38 targeting antibody, daratumumab, can be effectively and safely combined with lenalidomide-dexamethasone (1) and pomalidomide-dexamethasone in relapsed/refractory MM (2). Other CD38 antibodies such as isatuximab and TAK-079 are also effective in RRMM as single agent (12, 13). Moreover, recent phase 3 trials showed that addition of isatuximab to carfilzomib-dexamethasone or pomalidomide-dexamethasone improves response rate and PFS (14, 15).

In this issue, the paper entitled “The Role of Immunotherapy in Non-transplant Eligible Multiple Myeloma” by Bobin et al. describes how these SLAMF7 and CD38-targeting antibodies improve the outcome not only in young, but also in elderly MM patients. This is an important observation, since the improvement in outcome in elderly, non-transplant eligible patients, is less pronounced than in younger patients, most likely due to their increased susceptibility to treatment toxicity, which frequently results in treatment discontinuation (16). Indeed, elotuzumab and the CD38 antibodies proved to be well tolerated in both younger and elderly patients, also when combined with other anti-MM agents (17).
Patients, who develop disease that is resistant to PIs, IMiDs, and CD38 antibodies (triple-class refractory), have a very poor outcome, especially patients refractory to 2 PIs, 2 IMiDs, and a CD38 antibody (penta-refractory patients; median OS: 5.6 months) (18). The FDA and EMA recently approved belantamab mafodotin for the treatment of patients with relapsed or refractory MM who have received at least four prior therapies including an IMiD, a PI, and a CD38 antibody. Belantamab mafodotin is an antibody-drug conjugate that consists of a humanized B cell maturation antigen (BCMA)-specific IgG1 mAb fused to monomethyl auristatin F (MMAF) by a non-cleavable linker. Bruins et al. describe in their paper entitled “Targeted Therapy With Immunoconjugates for Multiple Myeloma” that belantamab mafodotin kills MM cells not only via the toxic effects of the microtubule disrupting agent MMAF, but also by immune-mediated mechanisms of action such as antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP). These pleiotropic mechanisms of action result in an approximately 30% response rate in triple-class refractory patients (19). Moreover, antibodies can be utilized as carriers of other effector moieties such as toxins, cytokines, or radionuclides. Bruins et al. also discuss the mechanisms of action, safety, and efficacy of several other promising immunoconjugates that are under investigation in preclinical and/or clinical MM studies.

In addition, chimeric antigen receptor (CAR) T-cells hold great promise for extensively pretreated MM patients. High response rates are obtained with BCMA-specific CAR T-cells (20, 21). However, studies with longer follow-up failed to show a plateau in the survival curves, indicating that CAR T-cell therapy needs further improvement. Van der Schans et al. describe in the manuscript entitled “Dual targeting to overcome current challenges in multiple myeloma CAR T-cell treatment” how CAR T-cell therapy can be improved in MM. The authors review other targets for CAR T-cell therapy and discuss how dual CAR targeting may lead to improved clinical outcomes by tackling target antigen loss or downregulation and by allowing the use of MM-associated, but not specific, target antigens.

The incorporation of new immunotherapeutic drugs in the treatment of MM has resulted in an increased rate of high-quality responses. However, several studies have shown that not all patients with a complete response, whereby light microscopy is used to define the percentage of tumor cells in the bone marrow, experience a prolonged survival (22). This indicates that more sensitive techniques are needed to detect the presence of tumor cells in the bone marrow. At this moment, minimal residual disease (MRD) can be detected by either multi-parameter flow cytometry or by next-generation sequencing, which reliably achieves $10^{-5}$ to $10^{-6}$ sensitivity for MM cell detection. Kostopoulos et al. discuss in their paper entitled “Minimal Residual Disease in Multiple Myeloma: Current Landscape and Future Applications With Immunotherapeutic Approaches” that MRD can be used as a prognostic factor, and they review how several trials are currently using MRD assessment to tailor treatment (e.g. guidance for type and duration of maintenance treatment).

Finally, the manuscript “Deregulation of Adaptive T Cell Immunity in Multiple Myeloma: Insights Into Mechanisms and Therapeutic Opportunities” by Leblay et al. describes how MM cells can escape immune-mediated attack in the immune-suppressive bone marrow microenvironment. In their review, novel insights are provided into the mechanisms that promote tumor escape, cause inadequate T-cell stimulation and impaired cytotoxicity in MM. Furthermore, the review highlights how adaptive T-cell immune responses can be restored in MM. A better understanding of these immune evasion strategies has resulted in the identification of novel targets for immunotherapy in MM. We expect that these insights will eventually lead to new immunotherapeutic strategies and further improvement in the survival of MM patients.

Overall, the different contributions show that immunotherapy has changed MM treatment and that in the nearby future the introduction of new immunotherapeutic approaches such as CAR T-cells, immunoconjugates, and bispecific antibodies, together with the use of more sensitive techniques to evaluate disease-response, will result in further improvement in the outcome of MM patients.

**AUTHOR CONTRIBUTIONS**

All authors contributed to the article and approved the submitted version.

**ACKNOWLEDGMENTS**

The Topic Editors thank all the contributors for submitting their work to this Research Topic, to the Review Editors and external Reviewers who participated in the review process, and to the Editorial and Production teams of Frontiers for their support through the various stages of the publication process.

**REFERENCES**

1. Dimopoulos MA, Lonial S, Betts KA, Chen C, Zichlin ML, Bruin A, et al. Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended 4-year follow-up and analysis of relative progression-free survival from the randomized ELOQUENT-2 trial. Cancer (2018) 124(20):4032–43. doi: 10.1002/cncr.31680

2. Dimopoulos MA, Dryfeldt D, Grossick S, Moreau P, Takezako N, Hori M, et al. Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma. New Engl J Med (2018) 379(19):1811–22. doi: 10.1056/NEJMoa1805762

3. Usmani S, Ailawadhi S, Sexton R, Hoerig A, Lipe BC, Hita S, et al. Primary analysis of the randomized phase II trial of bortezomib, lenalidomide, dexamethasone with/without elotuzumab for newly diagnosed, high-risk multiple myeloma (SWOG-1211). J Clin Oncol (2020) 38:8507. doi: 10.1200/JCO.2020.38.15_suppl.8507

4. Goldschmidt H, Mai E, Salwender H, Bertsch U, Miah K, Kunz C, et al. Bortezomib, lenalidomide and dexamethasone with or without elotuzumab as induction therapy for newly-diagnosed, transplant-eligible multiple myeloma. EHA (2020) 2023.

5. Mateos MV, Cavo M, Blade J, Dimopoulos M, Suzuki K, Jakubowiak A, et al. Daratumumab Plus Bortezomib, Melphalan, and Prednisone Versus
Bortezomib, Melphalan, and Prednisone in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Overall Survival in Alcyone. Blood (2019) 134:489. doi: 10.1182/blood-2019-123401

Mateos MV, Cavo M, Blade J, Dimopoulos MA, Suzuki K, Jakubiak A, et al. Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial. Lancet (2020) 395(10218):32–41. doi: 10.1016/S0140-6736(19)32956-3

Facon T, Kumar S, Plesner T, Orlowski RZ, Moreau P, Bahls N, et al. Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma. New Engl J Med (2019) 380(22):2104–15. doi: 10.1056/NEJMoai1817249

Moreau P, Attar M, Hulin C, Arnulf B, Belhadj K, Benboubker L, et al. Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study. Lancet (2019) 394(10192):29–38. doi: 10.1016/S0140-6736(19)31240-1

Dimopoulos MA, Oriol A, Nahi H, San-Miguel J, Bahls NJ, Usmani SZ, et al. Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma. N Engl J Med (2016) 375(14):1319–31. doi: 10.1056/NEJMoai1607751

Palumbo A, Chanana-Khan A, Weisel K, Nooka AK, Masszi T, Bekscac M, et al. Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma. N Engl J Med (2016) 375(6):754–66. doi: 10.1056/NEJMoai1606038

Usmani S, Quach H, Mateos MV, Landgren O, Leleu X, Siegel D. Carfilzomib, Dexamethasone, and Daratumumab Versus Carfilzomib and Dexamethasone for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma: Results of the Randomized Phase 3 Study CANDOR (NCT03158688). Blood (2019) 134:LBA–6. doi: 10.1182/blood-2019-132629

Krishnan AY, Patel K, Parameswaran H, Jagannath S, Niesvizky R, Silbermann R. Preliminary Results from a Phase 1b Study of TAK-079, an Investigational Anti-CD38 Monoclonal Antibody (mAb) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM). Blood (2019) 134:134. doi: 10.1182/blood-2019-128007

Mikhael J, Richter J, Vij R, Cole C, Zonder J, Kaufman JL, et al. A dose-finding Phase 2 study of single agent isatuximab (anti-CD38 mAb) in relapsed/refractory multiple myeloma. Leukemia (2020) 34(1):15–20. doi: 10.1038/s41375-019-0357-7

Moreau P, Dimopoulos M, Mikhael J, Yong K, Capra M, Facon T, et al. Isatuximab plus carfilzomib and dexamethasone vs carfilzomib and dexamethasone in relapsed/refractory multiple myeloma (IKEMA): Interim analysis of a phase 3 randomized, open-label study. EHA (2020) 2603. doi: 10.2217/fon-2019-0431

Atal M, Richardson PG, Rajkumar SV, San-Miguel J, Beksac M, Spicka I, et al. Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study. Lancet (2019) 394(10174):2096–107. doi: 10.1016/S0140-6736(19)63606-3

van de Donk NW, Moreau P, Plesner T, Palumbo A, Gay F, Laubach JP, et al. Clinical efficacy and management of monoclonal antibodies targeting CD38 and SLAMF7 in multiple myeloma. Blood (2016) 127(6):681–95. doi: 10.1182/blood-2015-10-646810

Gandhi UH, Cornell RF, Lakshman A, Gahvri ZJ, McGeehe E, Jagosky MH, et al. Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy. Leukemia (2019) 33(9):2266–75. doi: 10.1038/s41375-019-0435-7

Lonial S, Lee H, Badros A, Trudel S, Nooka AK, Chari A, et al. Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study. Lancet Oncol (2020) 21(2):207–21. doi: 10.1016/S1470-2045(19)30788-0

Raje N, Berdeja J, Lin Y, Siegel D, Jagannath S, Madduri D, et al. Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma. New Engl J Med (2019) 380(18):1726–37. doi: 10.1056/NEJMoai1817226

Berdeja J, Madduri D, Usmani S, Singh I, Zudaire E, Yeh T, et al. Update of CARTITUDE-1: A phase Ib/II study of JNI-4528, a B-cell maturation antigen (BCMA)-directed CAR-T-cell therapy, in relapsed/refractory multiple myeloma. J Clin Oncol (2020) 38:8505. doi: 10.1200/JCO.2020.38.15_suppl.8505

Lahwuera JI, Paiva B, Vidriales MR, Cordón L, Cedena MT, Puig N, et al. Depth of Response in Multiple Myeloma: A Pooled Analysis of Three PETHEMA/GEM Clinical Trials. J Clin Oncol (2017) 35(25):2900–10. doi: 10.1200/JCO.2016.69.2517

Conflict of Interest: ND has received research support from Janssen Pharmaceuticals, AMGEN, Celgene, Novartis, and BMS and serves in advisory boards for Janssen Pharmaceuticals, AMGEN, Celgene, BMS, Takeda, Roche, Novartis, Bayer, and Servier. EK has received honoraria/personal fees from Amgen, Genasis Pharma, Janssen, Takeda and Prothena and research grants from Amgen and Janssen. FG has received honoraria from Janssen Pharmaceuticals, AMGEN, Celgene, BMS, Takeda, Sanofi and serves in advisory boards for Janssen Pharmaceuticals, AMGEN, Celgene, BMS, Takeda, Roche, Abbvie, Sanofi, Oncopeptides and Adaptive.

Copyright © 2020 van de Donk, Kastritis and Gay. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.